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ABSTRACT
Nicotinic acetylcholine receptors can be assembled from either
homomeric or heteromeric pentameric subunit combinations. At
the interface of the extracellular domains of adjacent subunits
lies the acetylcholine binding site, composed of a principal
component provided by one subunit and a complementary
component of the adjacent subunit. Compared with neuronal
nicotinic acetylcholine cholinergic receptors (nAChRs) assem-
bled from a and b subunits, the a9a10 receptor is an atypical
member of the family. It is a heteromeric receptor composed
only of a subunits. Whereas mammalian a9 subunits can form
functional homomeric a9 receptors, a10 subunits do not
generate functional channels when expressed heterologously.
Hence, it has been proposed that a10might serve as a structural
subunit, much like a b subunit of heteromeric nAChRs, providing
only complementary components to the agonist binding site.
Here, we have made use of site-directed mutagenesis to
examine the contribution of subunit interface domains to
a9a10 receptors by a combination of electrophysiological and
radioligand binding studies. Characterization of receptors con-
taining Y190Tmutations revealed unexpectedly that both a9 and
a10 subunits equally contribute to the principal components of
the a9a10 nAChR. In addition, we have shown that the in-
troduction of a W55T mutation impairs receptor binding and
function in the rat a9 subunit but not in the a10 subunit,
indicating that the contribution of a9 and a10 subunits to
complementary components of the ligand-binding site is non-
equivalent. We conclude that this asymmetry, which is sup-
ported by molecular docking studies, results from adaptive
amino acid changes acquired only during the evolution of
mammalian a10 subunits.
Introduction
Nicotinic acetylcholine (ACh) receptors (nAChRs) are mem-
bers of the pentameric ligand-gated ion channel family (Nemecz
et al., 2016). Seventeen nAChR subunits (a1–a10, b1–b4, d, g,
and «) have been identified in vertebrates (Nemecz et al., 2016),
each of which has a large extracellular N-terminal region, four
transmembrane helices (M1–M4), and an intracellular domain
(Thompson et al., 2010). At the interface of the extracellular
domains of adjacent subunits lies the ACh binding site, formed
by six noncontiguous regions (loops A–F). Each binding site is
composed of a principal component or (1) face provided by one
subunit, which contributes three loops of highly conserved
residues (loops A–C), and a complementary component (2) of
the adjacent subunit, which contributes three loops (D–F) that
have lower levels of sequence conservation between subunits
(Brejc et al., 2001; Unwin, 2005; Dellisanti et al., 2007).
Consequently, the components of the extracellular intersubunit
binding sites are nonequivalent and their loops contribute
differently to receptor function (Karlin, 2002).
nAChRs can be assembled from either homomeric or
heteromeric subunit combinations (Millar and Gotti, 2009).
Homomeric receptors, such as a7, have five equivalent ACh
binding sites, each formed by the same principal and
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complementary components. ACh occupancy of one site is
enough for activation of the homomeric human a7 nAChR,
and also of a chimeric receptor containing the extracellular
domain of a7 and the transmembrane domain of the seroto-
nin type 3A (5-HT3A) receptor subunit (Rayes et al., 2009;
Andersen et al., 2013). However, whereas occupancy of three
nonconsecutive binding sites is required for maximal open-
channel lifetime of the chimeric receptor, only one functional
agonist binding site is required for maximal open-channel
lifetime in a7.
In contrast to homomeric nAChRs, heteromeric receptors can
have nonequivalent ACh binding sites provided by different
subunit interfaces. For example, the Torpedo nAChR has two
structurally different binding sites provided by the a(1)-d(2)
and a(1)-g(2) subunit interfaces (Martinez et al., 2000), which
bind agonists with different affinities (Blount andMerlie, 1989;
Prince and Sine, 1999). According to the known stoichiometries
of some neuronal nAChRs (Millar and Gotti, 2009), and by
analogy to the muscle-type receptor, it was originally thought
that heteromeric nAChRs have two agonist binding sites (Sine,
2002). In the case of neuronal nAChRs such asa4b2, a subunits
were thought to only provide the (1) site to the binding
interface, whereas b subunits were thought to provide the (2)
site (Arias, 1997; Luetje and Patrick, 1991). However, it was
subsequently shown that the composition of binding site
interfaces is more complex. For example, the a4b2 receptor
has two alternative stoichiometries, (a4)2(b2)3 and (a4)3(b2)2,
leading to different binding site configurations and resulting in
different functional and pharmacological properties (Carbone
et al., 2009; Harpsøe et al., 2011; Mazzaferro et al., 2011);
whereas (a4)2(b2)3 has two agonist binding sites provided by
a(1)-b(2) interfaces, (a4)3(b2)2 has a third a(1)-a(2) binding
interface (Hsiao et al., 2008; Mazzaferro et al., 2011).
The a9a10 receptor is an atypical member of the nAChR
family. It is a heteromeric receptor composed only of a subunits
(Elgoyhen et al., 1994, 2001; Sgard et al., 2002). Mammalian a9
subunits can form functional homomeric a9 receptors with an
EC50 for ACh similar to that of the heteromeric a9a10 receptor
(Elgoyhen et al., 1994, 2001). Hence, a9 subunits are capable of
providing principal and complementary components to func-
tional agonist binding sites. In contrast, rat and human a10
subunits do not lead to functional channels when expressed
heterologously (Elgoyhen et al., 2001; Sgard et al., 2002).
Consequently, it has been proposed that a10 might serve as a
structural subunit, much like a b subunit of heteromeric
receptors, providing only complementary components to the
agonist binding site (Elgoyhen and Katz, 2012). A (a9)2(a10)3
stoichiometry has been determined for the rat recombinant
receptor (Plazas et al., 2005), although expression of a 10-fold
excess of a9 compared with a10 in Xenopus oocytes can lead to
an additional receptor isoform with the stoichiometry
(a9)3(a10)2 (Indurthi et al., 2014). However, the relative contri-
bution of each subunit to the binding pockets of the heteromeric
a9a10 receptor is unknown. By a combination of approaches
(site-directed mutagenesis, expression studies, and molecular
docking) we show that, contrary to previous assumptions, a10
subunits do contribute to the principal component of the binding
site. Moreover, the contribution of a9 and a10 to the comple-
mentary component is nonequivalent. Our results demonstrate
the versatility of nAChR subunits to generate diverse binding
site interfaces with potentially different functional and/or
pharmacological properties.
Materials and Methods
Expression of Recombinant Receptors in Xenopus laevis
oocytes. cDNAs encoding Gallus gallus (chick) or Rattus norvegicus
(rat) a9 and a10 nAChR subunits were subcloned into a modified
pGEMHE vector for expression studies in Xenopus laevis oocytes.
Capped cRNAswere in vitro transcribed from linearized plasmidDNA
templates using RiboMAX Large Scale RNA Production System
(Promega,Madison,WI). Mutant subunits were produced using Quick
Change XL II kit (Stratagene, La Jolla, CA). Amino acid sequences
of rat and chicken a9, a10, and Torpedo a1 subunits were aligned
using ClustalW (EMBL-EBI, Wellcome Genome Campus, Hinxton,
Cambridgeshire). Residues were numbered according to the corre-
sponding Torpedo a1 subunit mature protein (Karlin, 2002).
The maintenance of Xenopus laevis and the preparation and cRNA
injection of stage V and VI oocytes have been described in detail
elsewhere (Verbitsky et al., 2000). Typically, oocytes were injected
with 50 nl of RNase-freewater containing 0.01–1.0 ng of cRNA (at a 1:1
molar ratio when pairwise combined) and maintained in Barth’s
solution at 18°C. Electrophysiological recordings were performed 2–
6 days after cRNA injection under two-electrode voltage clampwith an
Oocyte Clamp OC-725B or C amplifier (Warner Instruments Corp.,
Hamden, CT). Recordings were filtered at a corner frequency of 10 Hz
using a 900BTTunable Active Filter (Frequency Devices Inc., Ottawa,
IL). Data acquisition was performed using a Patch Panel PP-50 LAB/1
interface (Warner Instruments Corp.) at a rate of 10 points per second.
Both voltage and current electrodes were filled with 3 M KCl and had
resistances of ∼1 MV. Data were analyzed using Clampfit from the
pClamp 6.1 software (Molecular Devices, Sunnyvale, CA). During
electrophysiological recordings, oocytes were continuously superfused
(∼15 ml/min) with normal frog saline composed of: 115 mM NaCl,
2.5 mM KCl, 1.8 mM CaCl2, and 10 mM HEPES buffer, pH 7.2. ACh
was added to the perfusion solution for application. Unless otherwise
indicated, the membrane potential was clamped to 270 mV. To
minimize activation of the endogenous Ca21 sensitive chloride current
(Elgoyhen et al., 2001), all experiments were performed in oocytes
incubated with the Ca21 chelator 1,2-bis(2-aminophenoxy)ethane-N,
N,N9,N9-tetraacetic acid (acetoxymethyl ester) (100 mM) for 3 hours
before electrophysiological recordings.
Concentration-response curves were normalized to the maximal
agonist response in each oocyte. The mean and S.E.M. values of the
responses are represented. Agonist concentration-response curves were
iteratively fitted, using Prism 5 software (GraphPad Software Inc., La
Jolla, CA), with the equation: I/Imax 5 A
nH/(AnH 1 EC50
nH), where I is
the peak inward current evoked by the agonist at concentration A; Imax
is the current evoked by the concentration of the agonist eliciting a
maximal response; EC50 is the concentration of the agonist inducing a
half-maximal current response; andnH is theHill coefficient. Datawere
analyzed using Clampfit from the pClamp 6.1 software.
The effects of extracellular Ca21 on the ionic currents throughmutant
a9a10 receptors were studied by measuring the amplitudes of the
responses to an EC50 concentration of ACh upon varying the concentra-
tion of this cation from nominally 0 to 3 mM (Weisstaub et al., 2002).
Amplitude values obtained at each Ca21 concentration were normalized
to that obtained in the same oocyte at a 1.8 mM. Values from different
oocytes were averaged and expressed as the mean 6 S.E.M.
Radioligand Binding. Chimeric subunit cDNAs containing the
extracellular N-terminal domain of the a9 or a10 subunit fused to the
transmembrane and intracellular domain of the mouse 5-HT3A
subunit have been described previously (Baker et al., 2004). The
mammalian cell line tsA201 (derived from the human embryonic
kidney 293 cell line) was obtained fromDr. WilliamGreen (University
of Chicago, Chicago). Cells were cultured in Dulbecco’s modified
Eagle’s medium (Invitrogen, Paisley, United Kingdom) containing
2 mM L-GlutaMAX (Invitrogen) plus 10% heat-inactivated fetal calf
serum (Sigma, Poole, United Kingdom) with penicillin (100 U/ml) and
streptomycin (100 mg/ml) and were maintained in a humidified in-
cubator containing 5%CO2 at 37°C. Cells were transiently transfected
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using Effectene transfection reagent (QIAGEN, Crawley, United
Kingdom) according to the manufacturer’s instructions. In all cases,
cells were transfected overnight and assayed for expression approx-
imately 40–48 hours after transfection. To ensure that the levels of
radioligand binding were not influenced by differences in the amount
of subunit cDNA expressed, the amount of each subunit plasmid DNA
and also the total amount of plasmid DNA were kept constant when
subunitswere expressed singly and in combination. This was achieved
by the inclusion of empty plasmid expression vector when single
subunits were transfected.
Binding studies with [3H]-a-bungarotoxin (a-BTX) in cell mem-
brane preparations were performed essentially as described pre-
viously (Lansdell and Millar, 2000; Harkness and Millar, 2002).
Membranes (typically, 10–100 mg of protein) were incubated with
radioligand (final concentration 20 nM) for 150 minutes at 4°C in a
total volume of 300 ml in the presence of protease inhibitors leupeptin
(2 mg/ml) and pepstatin (1 mg/ml). Our standard protocol for de-
termining nonspecific binding was the addition of 1 mM carbachol,
1 mM nicotine, and 10 mM methyllycaconitine to triplicate samples.
Additional experiments were also performed in which nonspecific
binding of [3H]-a-BTX was determined by displacement of the radio-
ligand by ACh (1 mM). In all cases the levels of specific binding were
determined by subtracting the level of nonspecific binding from the
total binding (both of which were determined in triplicate). The data
were determined as means of three independent experiments, each
performed in triplicate. Radioligand binding was assayed by filtration
onto 0.5% polyethylenimine-presoakedWhatmanGF/B filters (Sigma-
Aldrich, Dorset, England) followed by rapid washing (typically, five
washes, each of 4 ml) with ice-cold 10 mM phosphate buffer using a
Brandel cell harvester, and radioactivity was determined by scintil-
lation counting. Care was taken to ensure that the number of receptor
binding sites used for binding studies was low enough to avoid
significant (.10%) ligand depletion at low concentrations of radio-
ligand. Preliminary experiments were conducted to ensure that
incubation times were long enough to enable radioligand binding to
reach equilibrium. Protein concentrations were determined using
bovine serum albumin standards (Bio-Rad, Hercules, CA).
Molecular Modeling and Docking. Homology models of the
extracellular domain of the chick and rat a9a10 nAChRs were created
with SWISSMODEL (Schwede et al., 2003; Arnold et al., 2006; Bordoli
et al., 2009) using themonomeric structure of the humana9 subunit as
the template (Protein Data Bank ID 4UY2) (http://www.rcsb.org/pdb/
explore/explore.do?structureId=4uy2) (Zouridakis et al., 2014). The
monomeric models of these proteins were then structurally aligned to
the pentameric structure of Lymnaea stagnalis AChBP bound to ACh
(Protein Data Bank ID 3WIP) (http://www.rcsb.org/pdb/explore/
explore.do?structureId=3wip) (Olsen et al., 2014) using the program
STAMP (Russell and Barton, 1992) from visual molecular dynamics
(Humphrey et al., 1996) to obtain pentameric models with a
(a9)2(a10)3 stoichiometry bound to ACh. Four different types of
possible binding site interfaces were included: a9a9, a9a10, a10a9,
and a10a10. In each interface, the first subunit forms the principal
face and the second forms the complementary face. The models were
energy minimized to relax steric clashes using spdbviewer (Guex and
Peitsch, 1997), and were used for docking studies after deletion of ACh
from the models. Using AutoDock version 4.3 (Morris et al., 2009),
ACh was docked into each of the four types of interfaces for rat and
chick subunits. Two hundred genetic algorithm runs were performed
for each condition. Residues R57, R111, and R117 were set as flexible
to avoid steric and/or electrostatic effects that may impair ACh
docking into the binding site.
Clustering of the results was done with AutoDock based on a root-
mean-square deviation cutoff of 2.0 Å. Docking results were corrobo-
rated in three different procedures. The most representative docking
result was plotted with Discovery Studio Visualizer 3.5 (Accelrys
Software, San Diego, CA).
Double-Mutant Cycle Analysis. The EC50 values were used to
determine the coupling coefficient V based on the following equation:
V5ECWR50 ECTM50
.
ECTR50 ECWM50
where WR corresponds to wild type; TM corresponds to the double
mutant W55TR117M; WM corresponds to the single mutant R117M;
and TR corresponds to the single mutant W55T. The coupling energy
between residues was calculated by the following equation (Schreiber
and Fersht, 1995):
DDG52RT lnðVÞ
Statistical Analysis. Statistical significance was determined
using analysis of variance (ANOVA) followed by the Bonferroni test.
Some of our data sets did not fit to a standard Gaussian distribution
when tested using Kolmogorov-Smirnov, D’Agostino-Pearson, or
Shapiro-Wilk tests. In those cases, statistical significance was evalu-
ated using nonparametric Mann-Whitney or Kruskal-Wallis tests
followed by Dunn’s tests. A P , 0.05 was considered significant.
All drugs were obtained from Sigma-Aldrich (St. Louis, MO), except
when otherwise indicated. ACh chloride was dissolved in distilled
water as 100 mM stocks and stored aliquoted at 220°C. 1,2-Bis(2-
aminophenoxy)ethane-N,N,N9,N9-tetraacetic acid (acetoxymethyl es-
ter) was stored at 220°C as aliquots of a 100 mM solution in
dimethylsulfoxide, thawed, and diluted 1000-fold into Barth’s solution
shortly before incubation of the oocytes. ACh solutions in Ringer’s
saline were freshly prepared immediately before application.
Experiments were carried out in accordance with the Guide for the
Care and Use of Laboratory Animals as adopted and promulgated by
the U.S. National Institutes of Health (https://grants.nih.gov/grants/
olaw/Guide-for-the-Care-and-Use-of-Laboratory-Animals.pdf), and were
approved by the Institution’s Animal Care and use Committee.
Results
The Principal Components of a9 and a10 Subunits
Contribute Equally to Function of Rat a9a10 nAChRs.
To determine the contribution of the principal components of
the a9 or a10 subunits to ligand binding and a9a10 nAChR
function, we generated Y190T mutant subunits (Torpedo
marmorata a1 numbering). Amino acid Y190 is a highly con-
served key residue in loop C of a nAChR subunits (Karlin,
2002). It has been shown to interact with ACh in a crystal
structure of a nAChR homolog from Lymnaea stagnalis (Olsen
et al., 2014) and with a-BTX when crystallized with either
the a1 (Dellisanti et al., 2007) and a9 receptor subunits
(Zouridakis et al., 2014) or a a7/AChBP chimera (Huang
et al., 2013). The substitution of Y190 by threonine profoundly
reduces binding and gating of the muscle AChR (Chen et al.,
1995) and prevents agonist-evoked responses in human a7
and a7/5-HT3A receptors (Andersen et al., 2013; Rayes et al.,
2009). Additionally, as a consequence of loop C movement
during ACh binding stabilization (Gao et al., 2006), Y190 has
been reported to disrupt a salt bridge associated with the
closed state of the receptor (Mukhtasimova et al., 2005).
We first evaluated specific total binding of [3H]-a-BTX in
nAChRs carrying the Y190T mutation. As previously de-
scribed (Baker et al., 2004), due to undetectable expression
levels in cell lines when expressing wild-type a9 or a10 sub-
units (Baker et al., 2004), binding studieswere performedwith
chimeric subunits containing the extracellular domain of rat
a9 or a10 subunits fused to the C-terminal domain of the
5-HT3A subunit (referred to as a9x and a10x, respectively).
Specific binding of [3H]-a-BTX was observed in cells tran-
siently transfected with either a9x or a10x, indicating
membrane targeting of homomeric receptors (Fig. 1). The
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coexpression of a9x and a10x resulted in significantly higher
levels of [3H]-a-BTX specific binding, which is likely to be a
consequence of more efficient assembly of the chimeric
subunits into heteromeric complexes as previously described
(Baker et al., 2004). Specific binding of [3H]-a-BTX to a9xa10x
was 6-fold higher than observed with a9x expressed alone
(n5 3,P, 0.0001,Kruskal-Wallis test followed byDunn’s test).
The introduction of the Y190T substitution into either a9x
or a10x (a9xY190T or a10xY190T) resulted in a complete loss
of specific binding of [3H]-a-BTX when expressed as either
homomeric or heteromeric (double-mutant) receptors (Fig. 1).
However, when either a9xY190T or a10xY190T was coex-
pressed with their nonmutated counterpart subunit (a9x or
a10x), specific [3H]-a-BTX binding was observed, indicating
that both a9 and a10 subunits can contribute to the principal
component of the extracellular ligand binding site. Specific
binding was 6-fold (n 5 3) and 4-fold (n 5 3) lower for
a9xY190Ta10x and a9xa10xY190T, respectively, compared
with wild-type a9xa10x (P , 0.0001, Kruskal-Wallis test
followed by Dunn’s test). However, specific binding of
a9xY190Ta10x was 4-fold higher than that observed for
homomeric a10x receptors, suggesting that mutant (Y190T)
subunits efficiently assemble into heteromeric receptors (P 5
0.0472, Mann-Whitney test).
To examine whether Y190T mutants are capable of forming
functional channels, receptors were heterogously expressed in
Xenopus laevis oocytes. Figure 2A shows representative
responses to increasing concentrations of ACh for wild-type
and Y190T mutant receptors. Both a9Y190Ta10 and
a9a10Y190T complexes formed functional channels. Maximal
ACh-evoked currents were similar for wild-type a9a10 and
a9a10Y190T mutants (Table 1) and were an order of magni-
tude larger than those previously reported for a9 homomeric
receptors (Elgoyhen et al., 2001), indicating that the resultant
responses are not due to the expression of a9 homomeric wild-
type receptors. Moreover, responses of a9Y190Ta10 receptors
derive from the incorporation of a9Y190T mutant subunits to
the heteromeric receptor since a9Y190T homomeric receptors
lack functional ligand binding sites (Fig. 1) and rat and human
a10 homomers are nonfunctional (Elgoyhen et al., 2001; Sgard
et al., 2002). Double-mutant a9Y190Ta10Y190T receptors
failed to respond to either 1 or 30 mM ACh (n 5 8), a result
consistent with the lack of binding sites (Fig. 1). As displayed
in Fig. 2B, the Y190T substitution in eithera9 ora10 produced
a shift of the ACh concentration-response curve to the right
and an increase in the ACh EC50 of two orders of magnitude
Fig. 2. Effect of the Y190T mutation on the response to ACh of rat a9a10
receptors. (A) Representative traces of responses evoked by increasing ACh
concentrations in oocytes expressing wild-type (upper panel), a9Y190Ta10
(middle panel), and a9a10Y190T (lower panel) receptors. (B) Concentra-
tion-response curves to ACh performed in oocytes expressing wild-type (s),
a9Y190Ta10 (u), anda9a10Y190T (◊) receptors. Peak current valueswere
normalized and refer to the maximal peak response to ACh in each case.
The mean and S.E.M. of 5–8 experiments per group are shown.
Fig. 1. Effect of the Y190T mutation on [3H]-a-BTX binding. Specific
binding levels of [3H]-a-BTX (final concentration 20 nM) to wild-type and
mutated (Y190T) subunit combinations expressed in mammalian tsA201
cells. Data are mean and S.E.M. of three independent experiments, each of
which was performed in triplicate.
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(Table 1). The increase in the EC50 of a9a10Y190T mutant
receptors compared with wild-type receptors once again
indicates that Y190T mutants are assembly competent, and
that responses do not derive from homomeric a9 wild-type
receptors. Taken together, these results suggest that both a9
and a10 can contribute with their principal components to the
binding site and that the integrity of both is necessary for wild-
type receptor function.
To further analyze the participation of the principal com-
ponents of both a9 and a10 to receptor function, wemutated to
serine the double cysteines of loop C, C192S/C193S [i.e.,
double cysteine to serine (CC/SS)], a hallmark of nAChR a
subunits (Karlin, 2002). Figure 3A shows representative
responses to increasing concentrations of ACh evoked in
Xenopus laevis oocytes expressing mutant receptors bearing
the CC/SS substitution in either a9 or a10 subunits, or both.
Surprisingly, the CC/SS double-mutant receptors were func-
tional. The CC/SS substitution in either a9 or a10 produced a
similar shift of the ACh concentration-response curve to the
right and an increase in the ACh EC50 of one order of
magnitude (EC50: wild type 5 18 6 3 mM; a9CC/SSa10 5
148 6 9 mM, n 5 8, P , 0.0001; a9a10CC/SS 5 147 6 17 mM,
n 5 17, P , 0.0001, one-way ANOVA followed by the
Bonferroni test) (Fig. 3B; Table 1). Further shift of the
concentration-response curve and an increase of the ACh
EC50 were observed in double-mutant CC/SS receptors (4056
13 mM, n 5 6, P , 0.0001 compared with wild type, one-way
ANOVA followed by the Bonferroni test).
Nonequivalent Contribution of a9 and a10 Comple-
mentary Components to Rat a9a10 nAChR Receptor
Function. To determine the contribution of the complemen-
tary faces of either a9 or a10 to rat a9a10 nAChR function, we
generated W55T mutant subunits. Amino acid W55 is highly
conserved within loop D of nAChR subunits, which contributes
to the complementary face of the ligand binding site (Karlin,
2002). The crystal structure of the ACh binding protein from
Lymnaea stagnalis bound to ACh shows a cation-p interaction
of W55 with this agonist (Olsen et al., 2014). Moreover, the
substitution of W55 by threonine in an a7/5-HT3A chimera
renders a receptor that binds a-BTX but impairs competition of
[3H]-a-BTX by ACh, leading to nonfunctional receptors (Rayes
et al., 2009). In addition, mutagenesis analysis in the Torpedo
electric organ nAChR has demonstrated thatW55 is part of the
ACh binding pocket of nAChRs (Xie and Cohen, 2001).
Figure 4 shows binding experiments performed with
[3H]-a-BTX in wild-type and W55T mutant a9a10 receptors.
In contrast to previous findings reported for the a7/5-HT3A
subunit chimera (Rayes et al., 2009), no detectable specific
binding was observed with homomeric a9xW55T receptors. In
contrast, homomeric a10xW55T receptors showed significant
levels of specific binding, similar to levels observed with
homomeric a10x (2.5 6 0.6 and 1.4 6 0.5 fmol/mg, respec-
tively, P 5 0.229, Mann-Whitney test). Consistent with these
results, heteromeric receptors containing a mutant a9xW55T
subunit (a9xW55Ta10x and a9xW55Ta10xW55T) showed
binding levels similar to those observed with either a10x or
a10xW55T when expressed alone (P5 0.1–0.7, Mann-Whitney
test). Moreover, receptors composed of wild-type a9x subunits
and mutated 10x (a9xa10xW55T) displayed specific binding
levels similar to those observed with wild-type heteromeric
a9xa10x receptors (P 5 0.114, Mann-Whitney test). Taken
together, these results indicate that the conserved amino acid
W55 in loop D is involved in the binding site of the a9a10
receptor only when provided by the a9 subunit. This appears to
suggest that the a9 subunit contributes to the complementary
component of the binding site ofa9a10 nAChRsand that the (2)
faces of a9 and a10 are nonequivalent.
An important question is whether ACh binds to
a9xa10xW55T receptors. To discriminate between total and
specific binding of [3H]-a-BTX we used a standard protocol in
which a mixture of cold ligands were used to determine
nonspecific binding. To confirm whether ACh itself is able to
displace binding of [3H]-a-BTX we repeated these binding
experiments and used only ACh to displace bound [3H]-a-BTX.
For both wild-type (a9xa10x) and mutated (a9xa10xW55T)
nAChRs, bound [3H]-a-BTX was displaced as efficiently with
ACh alone as with our standard mixture of nonradioactive
competing ligands, confirming that the ACh binding site is
retained in a9xa10xW55T. This indicates that the W55
mutation has a different effect in a10 to that observed with
the a9 subunit and its previously reported effect in a7 (Rayes
et al., 2009), and suggests that W55 contributes differently to
TABLE 1
Maximal evoked currents and concentration-response curve parameters
The number of experiments (n) represents independent oocytes from 3 to 6 different frogs. Asterisks (*) indicate the
results are significantly different from the control wild-type a9a10. Comparisons of EC50 values for wild-type, mutant a9,
mutant a10, or double-mutant receptors for each mutated residue were performed with one-way ANOVA followed by the
Bonferroni test.
Species Receptor Imax EC50 p n
nA mM
Rat a9a10 298 6 48 18 6 3 8
a9Y190Ta10 112 6 6 2254 6 155 ,0.0001* 5
a9a10Y190T 336 6 91 850 6 170 ,0.0001* 6
a9CC/SSa10 402 6 103 148 6 9 ,0.0001* 8
a9a10CC/SS 571 6 113 147 6 17 ,0.0001* 17
a9CC/SSa10CC/SS 360 6 119 405 6 13 ,0.0001* 6
a9W55Ta10 42 6 4 1022 6 35 ,0.0001* 5
a9a10W55T 177 6 81 36 6 1 0.0665 6
a9a10R117M 107 6 38 31 6 5 0.0655 5
a9a10 W55T/R117M 245 6 83 768 6 135 0.0011* 11
Chicken a9a10 100 6 12 16 6 2 6
a9W55Ta10 59 6 8 357 6 75 ,0.0001* 6
a9a10W55T 159 6 32 334 6 13 ,0.0001* 6
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the ACh binding site of the a9a10 receptor when provided by
the a9 or a10 subunit. Since W55 is a highly conserved key
residue present in loop D of nicotinic subunits that contributes
to complementary components of binding sites (Karlin, 2002),
the present results are consistent with the conclusion that a10
either does not contribute to the (2) face of the binding site of
the a9a10 receptor or that W55 of a10 is not readily accessible
within the binding pocket. If the latter is the case, then the
contributions of the (2) faces of a9 and a10 to the binding
interface are nonequivalent. To further examine these possi-
bilities, the functional responses of W55T mutated receptors
were studied in Xenopus laevis oocytes.
Figure 5A shows representative responses to increasing
concentrations of ACh in Xenopus laevis oocytes expressing
wild-type rat a9a10 receptors or W55T mutant receptors.
Double-mutant a9a10 receptors failed to evoke currents at
1 or 30 mM ACh (n 5 15). The W55T substitution in a9
produced a displacement of the concentration-response curve
to ACh to the right with a 60-fold increase in the EC50 (EC50:
wild type 5 18 6 3 mM, a9W55Ta10 5 1022 6 35 mM, P ,
0.0001, one-way ANOVA followed by the Bonferroni test, n 5
5–8) (Table 1). On the other hand, the W55T substitution in
a10 produced only a slight (although nonsignificant) increase
in the receptor EC50 (EC50: wild type 5 18 6 3 mM,
a9a10W55T 5 36 6 1 mM, P 5 0.0665 one-way ANOVA
followed by the Bonferroni test, n 5 6) (Table 1). Maximal
evoked currents of a9a10W55T receptors were not signifi-
cantly different from those of wild-type a9a10 receptors (Imax:
wild type 5 298 6 48 nA, a9a10W55T 5 177 6 81 nA, P 5
0.1826, Mann-Whitney test, n 5 6) (Table 1) and one order of
magnitude larger than those reported for a9 homomeric
receptors (Rothlin et al., 1999; Katz et al., 2000), indicating
that a10W55T is incorporated into a a9a10W55T heteromeric
receptor.
To further rule out the possibility that the modest effect
observed in responses to ACh of a9a10W55T receptors is due
to the lack of incorporation of the a10W55T subunit into a
heteromeric assembly, we analyzed the Ca21 sensitivity of the
resultant receptors. Homomeric a9 receptors are only blocked
by extracellular Ca21, whereas heteromeric a9a10 receptors
are potentiated in the submillimolar range and blocked at
higher concentrations of this divalent cation (Katz et al., 2000;
Weisstaub et al., 2002). Figure 5C shows the modulation
profile obtained at a concentration of ACh close to the EC50
(30 mM) value and the application of increasing concentra-
tions of extracellular Ca21. Peak current amplitudes at each
Fig. 3. Effect of the CC192/193SS (CC/SS) mutations on the response to
ACh of rat a9a10 receptors. (A) Representative traces of responses evoked
by increasing ACh concentrations in oocytes expressing a9CC/SSa10
(upper panel), a9a10CC/SS (middle panel), and a9CC/SSa10CC/SS (lower
panel) receptors. (B) Concentration-response curves to ACh performed in
oocytes expressing wild-type (s), a9CC/SSa10 (u), a9a10CC/SS (◊), and
a9CC/SSa10CC/SS (n) receptors. Peak current values were normalized
and refer to themaximal peak response to ACh in each case. Themean and
S.E.M. of 6–17 experiments per group are shown.
Fig. 4. Effect of the W55T mutation on [3H]-a-BTX binding. Specific
binding of [3H]-a-BTX (final concentration 20 nM) to wild-type and
mutated (W55T) subunit combinations expressed in mammalian tsA201
cells. Data are mean and S.E.M. of three independent experiments, each of
which was performed in triplicate.
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Ca21 concentration in each oocyte were normalized to those
obtained at 1.8 mM. Similar to that reported for wild-type
receptors (Elgoyhen et al., 2001; Weisstaub et al., 2002), a
biphasic Ca21 modulation profile was observed with maximal
responses at 0.5 mM. A one-way ANOVA followed by multiple
comparisons indicated that the difference in normalized mean
current amplitude between nominal 0 and 0.5 mM Ca21 is
significant (P 5 0.019, Kruskal-Wallis test followed by Dunn’s
test). This result demonstrates the occurrence of Ca21 potenti-
ation and thus confirms the incorporation ofa10W55T subunits
into pentameric receptors.
The functional results indicate that both a9 and a10
contribute to the (2) face of the intersubunit interface, but
that their contribution is nonequivalent. Thus, if a10 did not
contribute at all to the (2) face, the shift in the ACh
concentration-response curve of double-mutated W55T recep-
tors should resemble that of a9W55T receptors instead of
rendering nonfunctional receptors (Fig. 5B).
The a9 and a10 Subunits Contribute Equally to the
Complementary Component of the ACh Binding Site in
the Chicken a9a10 nAChR. The asymmetric contribution
of a9 and a10 subunits to the (2) face of the ACh binding site
might result from the adaptive evolution that occurred only in
mammalian CHRNA10 genes. This resulted in important
nonsynonymous amino acid substitutions in the coding region
of thea10 nAChR subunits, including that of loopD (Franchini
and Elgoyhen, 2006; Elgoyhen and Franchini, 2011; Lipovsek
et al., 2012). If this were the case, then both a9 and a10 should
equally contribute to the (2) face of the intersubunit interface
in a nonmammalian vertebrate species. Figure 6A shows
representative responses to increasing concentrations of
ACh evoked in Xenopus laevis oocytes expressing chicken
a9a10 wild-type and W55T mutant receptors. Double-mutant
receptors failed to evoke currents at 1 or 30 mM ACh (n5 10).
The W55T substitution in either a9 or a10 produced similar
shifts in the ACh concentration-response curves to the right
(Fig. 6) and a one order of magnitude increase in the receptor
EC50 (EC50: wild type 5 16 6 2 mM, a9W55Ta10 5 357 6
75 mM, a9a10W55T 5 334 6 13 mM, P , 0.0001, one-way
ANOVA followed by the Bonferroni test, n5 6) (Table 1). This
result suggests that, in contrast to the situation with rat
a9a10 receptors, in chicken the (2) face of both a9 and a10
subunits equally contribute to receptor function.
Molecular Docking of ACh in a9a10 Receptors. To
gain further insight into the contribution of the subunit com-
ponents to ACh binding, we modeled different subunit ar-
rangements to take into account the four possible subunit
interfaces [a9(1)a9(2), a9(1)a10(2), a10(1)a10(2), and
a10(1)a9(2)] in rat and chicken receptors, and performed
molecular docking studies. To evaluate the capability of each
interface to bind ACh, we compared the best binding energy
(BBE) (Fig. 7A) and the frequency of conformations that bind
the agonist in the correct orientation in the binding pocket
(Fig. 7B). For all interfaces, the conformations considered as
favorable were those showing the previously described cation-
p interactions between the amino group of ACh and aromatic
residues of the binding pocket (W55, Y93, W149, and Y190)
(Dougherty, 2007; Hernando et al., 2012) (Fig. 7C). In these
conformations, and for all interfaces, ACh shows the capability
to form hydrogen bonds with D119 and Y197, which are
equivalent to conserved H bonds of different nAChRs
(Tomaselli et al., 1991; Lester et al., 2004; Hernando et al.,
Fig. 5. Effect of the W55T mutation on the response to ACh of rat a9a10
receptors. (A) Representative traces of responses evoked by increasing ACh
concentrations in oocytes expressing a9W55Ta10 (upper panel) and
a9a10W55T (lower panel) receptors. (B) Concentration-response curves to ACh
performed in oocytes expressingwild-type (s), a9W55Ta10 (u), and a9a10W55T
(◊) receptors. Peak current valueswerenormalized and refer to themaximal peak
response to ACh. Themean and S.E.M. of 5–8 experiments per group are shown.
(C) Bar diagram illustrating the modulation of the a9a10W55T receptor by
extracellular Ca2+ exerts. Current amplitudes obtained at different Ca2+ concen-
trations in each oocytewere normalizedwith respect to that obtained at 1.8mMin
the same oocyte. Themean andS.E.M. of three experiments per group are shown.
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2012) (Fig. 7C). The BBE did not show important differences
among the different models, except for the homomeric rat
a10a10 interface. At this interface, the BBE was about 23.5
kcal/mol compared with25 to26 kcal/mol for all of the others
(Fig. 7A).
Themain difference in the docking results among interfaces
was detected in the frequency of favorable conformations (Fig.
7B). In rat, the most frequent conformations with ACh in the
correct orientation at the binding site was observed at the
interface in which a10 contributes to the principal and a9 to
the complementary face [a10(1)a9(2) interface], with a BBE
of 24.8 kcal/mol (Fig. 7). Models with rat the a10 subunit
placed in the complementary face [a9(1)a10(2) or a10(1)a
10(2)] showed a significant reduction of the frequency of
conformationswith ACh docked in the correct orientation (Fig.
7B). In the case of a10(1)a10(2), ACh only showed a favorable
orientation at the binding site in less than 2% of the
conformations in most of the docking conformations (Fig. 7B).
In chicken heteromeric interfaces, no significant differences
were observed in the frequency of favorable conformations
between the a9(1)a10(2) and a10(1)a9(2) interfaces. Thus,
in contrast to the rat nAChR, this suggests that a10 contrib-
utes similarly to both the principal and complementary faces
of the chicken receptor (Fig. 7). When comparing homomeric
interfaces, rat a10(1)a10(2) appears to be very unfavorable
for ACh binding (i.e., the lowest frequency of conformations
with ACh in the correct orientation and the highest BBE). In
chicken, both homomeric interfaces appear to be similarly
favorable for ACh binding, but less favorable than the
heteromeric ones (Fig. 7).
Taken together, the in silico studies support the experimen-
tal data indicating that in rat the contribution of a9 and a10 to
complementary components is nonequivalent. In contrast, a9
can form relatively appropriate interfaces for ACh binding
when placed at either the principal or complementary faces.
Moreover, the modeling supports the functional data for
chicken receptors, where a10 equally contributes to principal
and complementary components.
a10 Residue 117 in Loop E of the (2) Face Is a Major
Determinant of Functional Differences. Given that the
main key interactions at the binding site with aromatic
residues are conserved in all models in conformations where
ACh is bound in the correct orientation (Fig. 7), we analyzed in
more detail other residues that might account for the fact that
W55 is not a major determinant of rat a10 subunit comple-
mentary components, compared with rat a9 and chicken a9
and a10. Analysis of the model of ACh bound to the four
different types of interfaces [a9(1)a9(2), a9(1)a10(2),
a10(1)a10(2), and a10(1)a9(2)] shows that the residues on
a radial distribution of 5 Å are the same for the principal
components (Y93, S148, W149, Y190, C192, and Y197) and for
most of the complementary components (W55, R57, R79,
N107, V109, T/M/R117, andD119). They only differ at position
117, where the rat a10 positively charged arginine (R117)
which is highly conserved in mammalian a10 subunits, is
substituted by a noncharged methionine in chicken a10 and a
threonine or methionine in nonmammalian a10 subunits
(Figs. 7A and 8A); for an extended number of species see
Lipovsek et al. (2012, 2014). Interestingly, all a9 subunits
carry a threonine at this position. Moreover, the appearance of
the R117 nonsynonymous amino acid substitution in mam-
malian species has been under positive selection pressure
(Franchini and Elgoyhen, 2006). In many docking conforma-
tions R117 was placed toward the cavity (Fig. 7C). Moreover,
R117 had to be set as flexible to avoid steric and/or electro-
static effects that impair ACh docking into the correct binding
site (seeMaterials andMethods). In addition, rat a10 subunits
Fig. 6. Effect of the W55T mutation on the response to ACh of chicken
a9a10 receptors. (A) Representative traces of responses evoked by in-
creasing ACh concentrations in oocytes expressing wild-type (upper
panel), a9W55Ta10 (middle panel), and a9a10W55T (lower panel) chick
receptors. (B) Concentration-response curves to ACh performed in oocytes
expressing wild-type (s), a9W55Ta10 (u), and a9a10W55T (◊) chick
receptors. Peak current values were normalized and refer to the maximal
peak response to ACh. The mean and S.E.M. of six experiments per group
are shown.
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have a negatively charged glutamic acid residue E59 in loopD,
which is highly conserved and has been also positively selected
in mammalian species (Franchini and Elgoyhen, 2006), com-
pared with noncharged residues in nonmammalian a10 and
a9 subunits (Fig. 8A).
Because R117 and E59 are charged residues, due to the
long-range nature of electrostatic interactions, we analyzed
the distance distribution of protein-charged groups from the
positively charged N atom of ACh (Fig. 8B). In all interfaces,
the conserved residues observed on a radial distribution of
10 Å from this N atom were D119(2), R57(2), R79(2), D169(2),
and D199(1) in order of increasing distance. Here, the plus
and minus signs correspond to the presence of residues in
either the principal (1) or complementary (2) face, respec-
tively, and not to the charge of each residue. The most
significant difference was the positively charged R117 at a
Fig. 7. Docking of ACh into homology-modeled a9/a10 binding-site interfaces. AChwas docked in the correct orientation into the two possible models for
heteromeric interfaces of rat and chicken receptors. The BBE (A) and the percentage of favorable conformations (B) for bound ACh were averaged from
three different runs for each interface. (C) Representative models of ACh docked into the different interfaces. The main p-cation interactions are shown
with straight lines and the H-bonds are shown with dashed lines.
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distance of ∼8 to 9 Å from the ACh amino group, which was
only present in the complementary site of rat a10. This
relative excess in positively charged residues in rat a10 could
result in an unfavorable interaction with the ligand through
electrostatic repulsion and thus may perturb the binding site.
Interestingly, the negatively charged E59 is close to R117.
Although this residue could partially compensate for the
positive charge of R117, it is located more than 10 Å from
ACh, and thus its effect on the ligand is lower than that of
R117. Moreover, the analysis of positively and negatively
charged residues in the entire N-terminal domain of rat and
chick subunits indicates that the global balance is neutral in
rat a10, whereas it is strongly negative in rat a9 and chicken
a9 and a10 subunits. The difference is due to an excess of basic
residues (R and K) in rat a10 compared with the other
subunits (Table 2). Overall, these observations further con-
firm that the complementary faces of rat a9 and a10 subunits
are nonequivalent and that R117 in the complementary
component of a10 might account for functional differences.
We introduced the R117M substitution in the rat a10
subunit and expressed it in Xenopus oocytes with rat a9
(Fig. 9A). The a9a10R117M receptors were functional and
their ACh EC50 values, although slightly higher, did not
significantly differ from that of wild-type receptors (Table 1).
However, when W55 of a10R117M subunits was mutated to
threonine, a 43-fold shift in the ACh concentration-response
curve to the right was observed (EC50: wild type5 186 3 mM,
a9a10 W55T/R117M 5 768 6 135 mM, P 5 0.0011, one-way
ANOVA followed by the Bonferroni test, n 5 5–11) (Fig. 9;
Table 1). Thus, it appears that when theR117 is removed,W55
contributes to the (2) face of rat a10 subunits.
The typical way to analyze a system in which twomutations
are evaluated individually and in tandem is by mutant cycle
analysis (Schreiber and Fersht, 1995; Corradi et al., 2007).
Such analysis reveals whether the contributions from a pair of
residues are additive or if the effects of mutations are coupled.
We calculated the changes due to R117MandW55Tmutations
in the free energy of the responses using the EC50 values (Fig.
9B). Single-mutants a10W55T and a10R117M decreased the
free energy (20.40 and 20.32 kcal/mol, respectively); the
change in the free energy of the double mutant was signifi-
cantly different from the sum of the changes occurring in the
two single mutants (22.19 kcal/mol). To quantify energetic
coupling between a10W55 and a10R117 we analyzed the
changes in the free energy of coupling by double-mutant
thermodynamic cycles. When the EC50 values are cast as a
mutant cycle, the coupling coefficient is 12.4, which corre-
sponds to free energy coupling of 21.47 kcal/mol. Taken
together these results indicate that the effects of the muta-
tions are not independent and that the residues are coupled in
Fig. 8. The a9 and a10 subunit sequence alignments and distribution of charged residues. (A) Sequence alignments of part of the (2) face of a9 and a10
from different vertebrate species. Conserved W55 and mammalian positively selected E59 and R117 are shaded. (B) Distance (Å) of protein charged
groups from the nitrogen atom of ACh in chicken and rat receptors. The analysis was made using the theoretical models constructed by homology
modeling described inMaterials andMethods. The results are shown for the four types of interfaces: a9(+)a9(2), a9(+)a10(2), a10(+)a10(2), and a10(+)a
9(2). Positively charged groups are represented by black circles, whereas the negatively charged groups are represented by white circles. The identity of
each residue is shown.
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their contribution to function (Schreiber and Fersht, 1995;
Corradi et al., 2007).
Discussion
The present study shows that, contrary to previous assump-
tions, the a10 subunit contributes to the principal face of the
ligand binding site in the heteromerica9a10nAChR.Moreover,
we show that the contribution of rat a9 and a10 subunits to the
complementary face is nonequivalent. It is worth noting that
conotoxin RgIA, which potently blocks a9a10 nAChRs (Ellison
et al., 2006), was initially reported to bind to the a9(1)a10(2)
interface based on molecular modeling, docking, and molecular
dynamics simulations (Pérez et al., 2009). However, mutagen-
esis experiments have shown that conotoxins RgIA (Azam and
McIntosh, 2012; Azam et al., 2015) and Vc1.1 (Yu et al., 2013)
bind to the a10(1)a9(2) interface, further indicating that a10
contributes to the principal component of the binding site for
antagonist as well as agonist binding.
The lack of [3H]-a-BTX binding to homomeric (a9xY190Tand
a10xY190T) and heteromeric (a9xY190Ta10xY190T) nAChRs
is in agreement with the observation that Y190 in loop C of the
principal component interacts with a-BTX when crystallized
with either the a1 (Dellisanti et al., 2007), a9 (Zouridakis et al.,
2014), or an a7/AChBP chimera (Huang et al., 2013). Moreover,
Y190 has been shown to interactwithACh in a crystal structure
of a nAChR homolog from Lymnaea stagnalis (Olsen et al.,
2014). Therefore, the lack of binding of [3H]-a-BTX to Y190T
mutant receptors most likely also indicates disrupted ACh
binding sites. These binding experiments with Y190T mutated
receptors, together with the expression studies, indicate that
both a9 and a10 can contribute to the principal component of
the agonist binding site.
The fact that the mutation of the CC/SS mutant, a hallmark
of nAChR a subunits, in either a9 or a10 produced similar
rightward shifts in the concentration-response curves to ACh
further indicates that both subunits can equally contribute to
the principal components of the binding site. The observation
that a9CC/SSa10CC/SS double-mutant receptors were func-
tional, albeit with a further increase in the ACh EC50 value,
indicates that the ACh binding pocket is not completely
disrupted in the absence of the continuous double cysteines of
the principal component. This is in line with the observation
that in the crystal structure of the Lymnaea stagnalis nAChR
bound to ACh this agonist is wedged in between the disulfide
bridge of the double cysteine, but that interactions occur with
aromatic residues (Olsen et al., 2014). Likewise,mutation of the
CC in the Aplysia californica AChBP produces a 10-fold
decrease in affinity but does not abolish ACh binding (Hansen
and Taylor, 2007). Thus, it has been shown that loop C
contributes to the molecular recognition of the agonist by
moving into a capped position and locking the agonist in place
(Celie et al., 2004; Gao et al., 2005, 2006; Olsen et al., 2014).
Movement of loopC is also involved in the initial steps that lead
from binding to gating of the receptor (Sine and Engel, 2006).
The observation that the W55T mutation in loop D of the
complementary component of the a9 (but not the a10) receptor
subunit impaired [3H]-a-BTX binding most likely suggests a
disrupted agonist binding site, and therefore that a9 contrib-
utes to the complementary component of the ligand binding
site. In a crystal structure of a-BTX bound to a pentameric
a7/AChBP chimera, while Y190 in loop C is the main
contributor to the high-affinity toxin interaction through
p-cation and hydrogen bond interactions (Huang et al., 2013;
Sine et al., 2013) W55 contacts F32 of the toxin and its
mutation produces mild but significant reduction of a-BTX
binding affinity (Sine et al., 2013). The notion that a9
contributes to the complementary face of the binding site is
further supported by the docking analysis, where in rat
receptors the most frequent conformations with ACh in the
correct orientation at the binding site were observed at the
interface in which a10 contributes to the principal (1) and a9
to the complementary face (2) interface [a10(1)a9(2)]. Ex-
pression studies of mutant W55T receptors also indicate that
a9 complementary components contribute to receptor func-
tion. The increase in ACh apparent affinity of a9W55Ta10
might also result from reduced gating kinetics. In this regard,
mutations in this residue in themuscle receptor affect channel
gating due to a reduction in the channel opening rate constant
(Akk, 2002).
Fig. 9. Effect of the R117M mutation on rat a9a10 receptors. (A)
Concentration-response curves to ACh performed in oocytes expressing
wild-type (s), a9a10R117M (u), and a9a10W55T/R117M (◊) double-
mutant rat receptors. Peak current values were normalized and refer to
the maximal peak response to ACh. The mean and S.E.M. of 5–11
experiments per group are shown. (B) Scheme for double-mutant cycle
analysis. DDG values corresponding to each mutant are shown. These
valueswere calculated as2RTln(EC50mutant/EC50wild type). The coupling
parameter, V, was calculated as indicated inMaterials and Methods.
TABLE 2
Number of charged residues in rat and chicken a9 and a10 subunits
The basic-acidic balance was calculated as the difference in the number of basic
(R and K) compared with acidic (D and E) amino acid residues.
Species Subunit Acidic (D and E) Basic (R and K) Basic-Acidic Balance
Rat a9 34 16 218
a10 24 24 0
Chick a9 33 18 215
a10 28 18 210
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The fact that the a9xa10xW55Tmutation bound [3H]a-BTX
(and this was displaced byACh), togetherwith the finding that
the a9a10W55T mutant receptors had similar ACh apparent
affinity and macroscopic currents to wild-type receptors,
indicates that either a10 does not contribute to the comple-
mentary face of the binding pocket or that a10 might in-
efficiently provide the (2) face since W55 in loop D cannot
make the proper cation-p interactions with ACh. The latter is
rather unexpected, since W55 is a key contributor of the (2)
face to ACh binding in all nAChRs (Karlin, 2002; Olsen et al.,
2014). However, it can explain the observation that a10
contributes to the complementary face in the presence of
disrupted a9(2) faces, as observed in functional studies with
a9W55Ta10 receptors. Therefore, one could conclude that in
rat heteromeric a9a10 receptors the contribution of a10 to the
complementary component is nonequivalent to that of a9 since
it does not involve equally W55, a key residue for ACh binding
and gating. This resembles what has been described for the
Torpedo and muscle embryonic nAChRs, where the contribu-
tion of the g and d subunits to the (2) face is nonequivalent
(Sine and Claudio, 1991; Martin et al., 1996; Xie and Cohen,
2001). Overall the functional results are in line with the
in silico modeling, which showed a significant reduction in the
frequency of conformations with ACh docked in the correct
orientation with the rat a10 subunit placed in the comple-
mentary face, a9(1)a10(2) or a10(1)a10(2).
The observation that in chicken receptors the introduction
of the W55T mutation in either a9 or a10 produced similar
shifts in the ACh apparent affinity of resultant heteromeric
receptors indicates that both a9 and a10 can equally contrib-
ute to the (2) face of the binding pocket. This is supported by
the observation that, contrary to that observed for rat
receptors, in chicken molecular docking studies indicate that
the frequency of ACh bound in the correct orientation is
similar for either a9(1)a10(2) ora10(1)a9(2) interfaces. This
might explain that, in contrast to that observed for rat
subunits (Elgoyhen et al., 2001; Sgard et al., 2002), chicken
homomeric a10 receptors are functional when expressed in
Xenopus laevis oocytes (Lipovsek et al., 2014).
The asymmetry between rat and chicken receptors most
likely derives from the acquisition of nonsynonymous substi-
tutions in the complementary face of mammalian a10 sub-
units (Franchini and Elgoyhen, 2006). R117 present in
mammalian a10 subunits, but replaced by a noncharged
methionine or threonine in nonmammalian a10 subunits and
threonine in vertebrate a9 subunits (Fig. 8), might account for
the fact that W55 does not equivalently contribute to receptor
function when comparing rat a10 to rat a9, chicken a9, and
chicken a10 subunits. Its presence might result in a positively
charged environment that would perturb the access of the
quaternary ammonium of ACh to the binding pocket. This
resembles what has been recently described in the crystal
structure of the a4b2 nAChR, where three hydrophobic groups
on the (2) side of the b2 subunit are replaced by polar side
chains on the (2) side of the a4 subunit. It has been suggested
that this difference in chemical environment may affect
agonist binding to a4–a4 interfaces in the (a4)3(b2)2 stoichio-
metry, being a polar environment less favorable for agonist
binding (Morales-Perez et al., 2016). Understanding the un-
derlying mechanisms accounting for the perturbation pro-
duced by R117 in the (2) face of the rat a10 subunit would
require further experiments, including determination of the
crystal structure of the a9a10 receptor bound to ACh.
However, by double-mutant cycle analysis we have been able
to show that W55 and R117 are coupled to each other in their
contribution to nAChR function. Thus, the mutation at one
site has structural or energetic impact at a second site.
Typically, a value of V that deviates significantly from 1 is
interpreted as a direct interaction between residues, such as
that provided by a hydrogen bond or a salt bridge. However,
the molecular structure of the a9a10 nAChR (Fig. 7) shows
that W55 and R117 are not in close apposition and appear
separated by about 10 Å, thus suggesting that the coupling
does not arise froma direct interaction. The occurrence of long-
range functional coupling between residues in which a direct
interaction is precluded has been described in the mouse
muscle nAChR (Gleitsman et al., 2009).
In conclusion, we have demonstrated that whereas both a9
and a10 contribute to the principal component of a9a10
nAChRs their contribution to the complementary face of the
binding pocket in rat a9a10 nAChRs is nonequivalent. This
results from the adaptive evolutionary amino acid changes
acquired by mammalian a10, which rendered a divergent
branch within the clade of vertebrate a10 subunits (Lipovsek
et al., 2012).
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